• DOI:10.1177/0091270005277935
Corpus ID: 24350277

Clinical Pharmacology of Rasagiline: A Novel, Second‐Generation Propargylamine for the Treatment of Parkinson Disease

@article{Chen2005ClinicalPO,
  title={Clinical Pharmacology of Rasagiline: A Novel, Second‐Generation Propargylamine for the Treatment of Parkinson Disease},
  author={J. Chen and D. Swope},
  journal={The Journal of Clinical Pharmacology},
  year={2005},
  volume={45}
}

J. Chen, D. Swope

Published 2005

Medicine

The Journal of Clinical Pharmacology

Rasagiline is a novel second‐generation propargylamine that irreversibly and selectively inhibits monoamine oxidase type B (MAO‐B). For the management of Parkinson disease (PD), rasagiline is efficacious across the span of PD stages ranging from monotherapy in early disease to adjunctive treatment in patients with advancing disease and motor fluctuations. Rasagiline completely and selectively inhibits MAO‐B with a potency 5 to 10 times greater than selegiline. Unlike the prototype… CONTINUE READING

View on Wiley

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed